Allogeneic Cord Blood Transplantation

Yıl 2015, Cilt: 24 Sayı: 2, 195 - 210, 05.03.2015

Banu Oflaz Sözmen Mehmet Ertem

https://doi.org/10.17827/aktd.06819

Öz

Allogeneic hematopoietic stem cell transplantation is an established treatment modality for many malignant and benign hematologic, metabolic and immunologic disorders. Cord blood has been used as an alternative to bone marrow and peripheral blood as the graft source. The clinical experience with cord blood transplantation has gradually increased both in pediatric and adult patient populations. So far double cord blood transplantation, in vitro expansion of cord blood unit and infusion of the cord blood into bone marrow space has been studied to expand the clinical applications of cord blood transplantation. The HLA match between the selected units as well as the patient, nucleated cell number of the transfused unit(s) have been shown to be most important in the unit selection.

Anahtar Kelimeler

cord blood transplantation; hematopoietic stem cell transplantation; HLA

Allojenik Kordon Kanı Transplantasyonu

Öz

Allojenik hematopoetik kök hücre transplantasyonu günümüzde maliyn ve maliyn olmayan pek çok
hematolojik ve metabolik hastalıkta, immün yetmezlik sendromlarında küratif bir tedavi yöntemi
olarak kullanılmaktadır. Kordon kanının kemik iliği ve periferik kana alternatif kök hücre kaynağı
olarak kullanımı uygun vericiye ulaşımın güçlüğü nedeni ile gündeme gelmiş ve özellikle son on yılda
pediatrik ve yetişkin yaş gruplarında klinik uygulamalarda yerini almıştır. Günümüzde kordon kanı
transplantasyonunun yaygınlaştırılması için çift kordon kanı ünitesi kullanılması, kordon kanının nakil
öncesi sayıca çoğaltılması ve kemik iliği içine infüzyonu gibi uygulamalar kullanılmaktadır. Kordon
kanı transplantasyonunda tedavi başarısını belirlemede seçilen kordon kanı üniteleri ve alıcı arasındaki
HLA uyumu ile verilen çekirdekli hücre sayısı önem kazanmaktadır.

Anahtar Kelimeler

kordon kanı transplantasyonu, hematopoetik kök hücre transplantasyonu, HLA

Kaynakça

• Ballen KK, King RJ,Chitphakditi P, Bolan CD, Agora E, Hartzman RJ et al, The National Marrow Donor Program experience:the first 20 years of unrelated donor stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:2-7
• Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2002;29:639-46.
• Çetin M, Ertem M. Çocukluk çağı hastalıklarında kemik iliği transplantasyonu endikasyonları. Katkı. 2002;23:540-50.
• Appelbaum FR. Pursuing the goal of a donor for everyone in need. N Eng J Med. 2012;367:1555- 6.
• Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122:491-98.
• Knudtzon S. In vitro growth of granulocyte colonies from circulating cells in human cord blood. Blood. 1974;43:357-61.
• Gabutti V, Foa R, Mussa F, Aglietta M. Behavior of human hematopoietic stem cells in cord and neonatal blood. Haematologica. 1975;4:60-8.
• Wagner JE, Kurtzberg J. Allogeneic umbilical cord blood transplantation. In Cellular Characteristics of Cord Blood Transplantation (Ed HE Broxmeyer):113-45: Maryland, AABB Press Bethesda, 1998.
• Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, English D et al. Human umbilical cord blood as a source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA.
• Broxmeyer HE. The past, present, and future of cord blood transplantation. In:. Cellular Characteristics of Cord Blood Transplantation (Ed HE Broxmeyer):1-9. Maryland, AABB Press Bethesda, 1998.
• Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical cord- blood from HLH-identical sibling. N Eng J Med. 1989;321:1174-8.
• Wagner JE, Broxmeyer HE, Byrd RL, Zehnbauer B, Schmeckpeper B, Shah N et al. Transplantation of umbilical cord-blood after myeloablative therapy: analysis of engraftment. Blood. 1992;79:1874-81.
• Vilmer E, Sterkers G, Rahimy C, Denamur E, Elion J, Broyart A et al. HLA-mismatched cord blood transplantation in a patient with advanced leukemia. Transplantation. 1992;53:1155-7.
• Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E et al. Allogeneic sibling umbilical cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 1995;346:214-9.
• Kurtzberg J, Laughlin M, Graham M, Smith C, Olson JF, Halperin EC et al. Placental blood as a source of hematopoietic stemm cells for transplantation into unrelated recipients. N Eng J Med
• Noort WA, Falkenburg JHF. Hematopoietic content of cord blood. In: Cord Blood Characteristics: Role in Stem Cell Transplantation (Eds SBA Cohen, E Gluckman, A Madrigal):13-37, London, Martin Dunitz, 2000.
• Garderet L, Dulphy N, Douay C, Chalumeau N, Schaeffer V, Zilber MT, et al. The umbilical cord- blood αβ T-cell repertoire: characteristics of a polyclonal and naïve but completely formed repertoire. Blood. 1998;91:340-6.
• De La Sella V, Gluckman E, Bruley-Rosset M. Graft versus host disease and graft versus leukemia effect in mice grafted with newborn blood. Blood. 1998;92:3968-73.
• Broxmeyer HE, Lee MR, Hangoc G, Cooper S, Prasain N, Kim YJ, et al.Hematopetic stemprogenitor cells, generation of induced pluripotent stem cell, and isolation of endothelial progenitors from 21- to 23.5 year cryopreserved cord blood. Blood. 2011;117:4773-77
• Vormoor J, Lapidot T, Pflumio F, Risdon G, Patterson B, Broxmeyer HE, et al. Immature human cord blood progenitors engraft and proliferate to high levels in SCID mice. Blood. 1994;83:2489- 97
• Gluckman E, Rocha V, Boyer Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Eng J Med 1997;337:373-9.
• Rocha V, Wagner JE, Sobocinski KA, Klein JP, Zhang MJ, Honowitz MM, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA- identical sibling. N Eng J Med. 2000;342:1846-54.
• Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, Bernaudin F, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA identical sibling. Blood. 2013;122:1072-8.
• Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97:2962-71.
• Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, et al. Outcomes of tranplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia; a comparison study. Lancet. 2007;369:1947-54
• Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adults and pediatric patients. Biol. Blood Marrow Transplant. 2007;13:444-53.
• Ruggeri A, Eapen M, Scaradavou A, Cairo MS, Bhatia M, Kurtzberg J et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17:1375-82.
• Gluckman E, Rocha V, Ionescu I, Bierings M, Harris RE, Wagner , et al. Results of unrelated cord blood transplant in Fanconi anemia patients. Biol Blood Marrow transplant. 2007;13:1073-82.
• Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoetic engraftment and survival in adult recipients of umbilical cord blood from unrelated donors. N Engl J Med. 2001;344:1815-22.
• Takahashi S, Iseki T, Ooi, J, Tommonari A, Takasugi K, Shimohakamada Y et al, Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813-20.
• Cohen YC, Scaradavou A, Freedman LS, Rubinstein P, Gluckman E, Rocha V et al. Factors affecting mortality following myeloablative cord blood transplantation in adults:A pooled analysis of three international registries. Bone Marrow Transplant. 2011;46:70-6.
• Sanz GF, Saavedra S, Planelles D, Senent L, Cervera J, Barragain E et al. Standarized, unrelated donor cord blood transplantation in adults with hematological malignancies. Blood. 2001;98:2332-8.
• Ballen KK, Spitzer T, Antin JH, McAfee S, Dey BR, Attar E et al. Double unrelated reduced intensity umbilical cord blood transplantation in adults. Blood Marrow Transplant. 2007;13:82-9.
• Avery S, Shi W, Lubin M, Gonzales AM, Heller G, Castro-Malaspina H et al. Influence of infused cell dose and HLA match on engraftment after double unit cord blood allografts. Blood.
• Delaney C, Varnum-Finney B, Aoyama K, Brasham-Stein C, Bernstein ID. Dose dependent effects of the Notch ligand Delta 1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood. 2005;106:2693-9.
• Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16:232-6.
• Delaney C, Bollard CM, Shpall EJ. Cord blood engineering. Biol Blood Marrow Transplant. 2013;19:74-8.
• Robinson SN, Ng J,Niu T, Yang H, McMannis JD, Karandish S et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006;37:359-66.
• de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M et al. Cord blood engraftment with ex vivo mesenchymal cell coculture. N Engl J Med. 2012;367:2305-15.
• Rocha V, Labopin M, Ruggeri A, Podesta M, Gallamini A, Bonifazi F et al. Unrelated cord blood transplantation:outcomes after single unit intrabone injection compared with double unit intravenous injection in patients with hematological malignancies. Transplantation
• Kamani N, Spellman S, Hurley CK, Barker JN, Smith FO, Oudshoorn M et al; State of the art review: hla matching and outcome of unrelated donor umbilical cord blood transplants. Biol. Blood Marrow Transplant. 2008;14:1-6.
• Gluckman E. Cord blood transplantation. Biol Blood Marrow Transplant. 2006;12:808-12.
• Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant. 2008;41:207-14.
• Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients. Blood. 2010;115:1843-9.
• Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Arasetti C et al. Effect of donor recipient HLA matching at A, B, C and DRB1 on outcomes after umbilical cord blood transplantation for leukemia and myelodysplastic syndrome. Lancet Oncol. 2011;12:1214-21.
• Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C et al. Impact of allele level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133-40.
• Rocha V, Spellman S, Zhang MJ, Ruggeri A, Purtill D, Brady C et al. Effect of HLA-matching recipients to donor non-inherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2012;18:1890-6.
• Correspondence Address / Yazışma Adresi